More information: KeJing Zhang et al, A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer, Cell Chemical Biology (2024).

TOPLINE: Patients with early-stage triple-negative breast cancer (TNBC) and high immune infiltration showed improved disease-free survival (DFS) with adjuvant capecitabine. These “immune-hot ...

Key Takeaways Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The ...

Key Takeaways Deescalated nab-paclitaxel plus carboplatin showed higher efficacy than nab-paclitaxel plus gemcitabine in early-stage TNBC patients. BRCA1/2 mutation carriers exhibited a more ...

VERITAC-2 This trial was emblematic of the rising importance of biomarker testing in cancer care, a theme seen across ASCO 2025. PROTACs are often compared with SERDs, which enable ER degration ...

Patients with stage I triple-negative breast cancer (TNBC) who have higher levels of stromal tumor-infiltrating lymphocytes (TILs) demonstrate "excellent" 10-year breast cancer–specific survival ...

More than 10% of new triple-negative breast cancer cases could be avoided if women breastfed or pumped for longer than 6 months, according to results of a retrospective analysis.Between 3,000 and ...

ZEST included patients with stage I-III triple negative breast cancer (TNBC), or BRCA -mutated HER2-BC. Testing for ctDNA-based MRD began any time after the end of definitive treatment, and those ...

Triple-negative breast cancer lacks the expression of estrogen, progesterone and HER2 receptors, and so it makes it unresponsive for standard hormonal therapies targeting HER2.